Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

McMaster University

$150,000.00

Stakeholder perspectives and preferences on the implementation of pharmacogenomic (PGx) testing in primary care in Ontario, Canada.

EF 2021-22

Résumé
It is increasingly understood that drug response is partly influenced by genetics. Using pharmacogenomic (PGx) testing, it is possible to determine whether individuals possess genetic variant(s) involved in drug response. Implementation of PGx testing might lead to fewer adverse drug reactions and greater adherence to prescribed medications. PGx testing may be particularly useful in primary care since this is where most medication prescription and dispensation occurs and 60% of primary care patients are prescribed a drug for which PGx information is available. Despite this, PGx testing is not yet widely performed in the clinical setting and in Canada has not been implemented at all in primary care. This may be due to lack of evidence on PGx test accuracy; lack of economic evidence; or patient concerns (for example, regarding privacy). Given the benefits and challenges of PGx testing, stakeholder evidence is needed to inform whether and how this type of testing should be implemented in primary care. This research examines stakeholder perspectives and preferences to inform health policy and funding decision making about implementation of PGx testing in primary care. I will conduct three studies. First, I will review PGx clinical practice guidelines from around the world to understand when and for whom this type of testing is appropriate. Next, I will conduct semi-structured interviews with stakeholders such as patients, primary care providers, and policy makers about their views on implementation and public coverage of PGx testing. Finally, I will conduct a discrete choice experiment (DCE) in which participants will be asked to choose between different hypothetical policy options for PGx testing. I will compare interview results with DCE results to understand how stakeholders' stated versus actual preferences differ. This research will contribute to developing PGx policy that reflects stakeholders' preferences and values.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
457486
Name
Cernat Alexandra
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Stakeholder perspectives and preferences on the implementation of pharmacogenomic (PGx) testing in primary care in Ontario, Canada.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Discrete Choice Experiment; Genetic Testing; Health Policy; Health Services Research; Health Technology Assessment; Mixed Methods; Pharmacogenomics; Qualitative Methods; Stakeholder Engagement
Abstract
It is increasingly understood that drug response is partly influenced by genetics. Using pharmacogenomic (PGx) testing, it is possible to determine whether individuals possess genetic variant(s) involved in drug response. Implementation of PGx testing might lead to fewer adverse drug reactions and greater adherence to prescribed medications. PGx testing may be particularly useful in primary care since this is where most medication prescription and dispensation occurs and 60% of primary care patients are prescribed a drug for which PGx information is available. Despite this, PGx testing is not yet widely performed in the clinical setting and in Canada has not been implemented at all in primary care. This may be due to lack of evidence on PGx test accuracy; lack of economic evidence; or patient concerns (for example, regarding privacy). Given the benefits and challenges of PGx testing, stakeholder evidence is needed to inform whether and how this type of testing should be implemented in primary care. This research examines stakeholder perspectives and preferences to inform health policy and funding decision making about implementation of PGx testing in primary care. I will conduct three studies. First, I will review PGx clinical practice guidelines from around the world to understand when and for whom this type of testing is appropriate. Next, I will conduct semi-structured interviews with stakeholders such as patients, primary care providers, and policy makers about their views on implementation and public coverage of PGx testing. Finally, I will conduct a discrete choice experiment (DCE) in which participants will be asked to choose between different hypothetical policy options for PGx testing. I will compare interview results with DCE results to understand how stakeholders' stated versus actual preferences differ. This research will contribute to developing PGx policy that reflects stakeholders' preferences and values.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Cernat, Alexandra
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~